bluebird bio Inc (BLUE.OQ)
BLUE.OQ on NASDAQ Stock Exchange Global Select Market
125.24USD
19 Oct 2018
125.24USD
19 Oct 2018
Change (% chg)
$3.10 (+2.54%)
$3.10 (+2.54%)
Prev Close
$122.14
$122.14
Open
$123.40
$123.40
Day's High
$125.85
$125.85
Day's Low
$122.00
$122.00
Volume
15,089
15,089
Avg. Vol
252,038
252,038
52-wk High
$236.05
$236.05
52-wk Low
$120.02
$120.02
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -2.88 | December | 19 Oct 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 5 | 5 | 5 | 5 |
| (2) OUTPERFORM | 9 | 9 | 9 | 9 |
| (3) HOLD | 7 | 7 | 6 | 6 |
| (4) UNDERPERFORM | 1 | 1 | 1 | 1 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.18 | 2.18 | 2.14 | 2.14 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 15 | 7.59 | 11.20 | 5.00 | 5.49 |
| Quarter Ending Mar-19 | 10 | 8.84 | 19.80 | 5.00 | -- |
| Year Ending Dec-18 | 19 | 39.49 | 47.00 | 33.00 | 27.20 |
| Year Ending Dec-19 | 21 | 84.73 | 537.17 | 11.00 | 86.95 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | 17 | -2.88 | -2.41 | -3.19 | -1.65 |
| Quarter Ending Mar-19 | 10 | -2.87 | -2.27 | -3.41 | -- |
| Year Ending Dec-18 | 19 | -10.88 | -9.39 | -11.52 | -7.12 |
| Year Ending Dec-19 | 21 | -11.01 | -1.01 | -13.79 | -6.63 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Jun-18 | 9.64 | 7.85 | 1.79 | 18.58 |
| Quarter Ending Mar-18 | 5.60 | 15.96 | 10.36 | 185.11 |
| Quarter Ending Dec-17 | 7.06 | 4.17 | 2.89 | 40.93 |
| Quarter Ending Sep-17 | 7.07 | 7.71 | 0.64 | 9.06 |
| Quarter Ending Jun-17 | 5.21 | 16.72 | 11.51 | 220.88 |
| Earnings (per share) | ||||
| Quarter Ending Jun-18 | -2.35 | -2.91 | 0.56 | -24.01 |
| Quarter Ending Mar-18 | -2.07 | -2.31 | 0.24 | -11.70 |
| Quarter Ending Dec-17 | -1.70 | -2.52 | 0.82 | -48.14 |
| Quarter Ending Sep-17 | -1.71 | -1.73 | 0.02 | -1.38 |
| Quarter Ending Jun-17 | -1.65 | -1.73 | 0.08 | -4.56 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 7.59 | 7.59 | 8.09 | 8.31 | 5.49 |
| Quarter Ending Mar-19 | 8.84 | 8.84 | 8.99 | 9.45 | -- |
| Year Ending Dec-18 | 39.49 | 39.48 | 40.38 | 40.56 | 27.20 |
| Year Ending Dec-19 | 84.73 | 84.73 | 86.57 | 87.84 | 86.95 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | -2.88 | -2.88 | -2.88 | -2.87 | -1.65 |
| Quarter Ending Mar-19 | -2.87 | -2.87 | -2.86 | -2.83 | -- |
| Year Ending Dec-18 | -10.88 | -10.88 | -10.85 | -10.81 | -7.12 |
| Year Ending Dec-19 | -11.01 | -11.01 | -10.89 | -10.80 | -6.63 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Dec-18 | 0 | 0 | 0 | 1 |
| Quarter Ending Mar-19 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 1 | 0 | 1 | 2 |
| Year Ending Dec-19 | 0 | 0 | 0 | 2 |
| Earnings | ||||
| Quarter Ending Dec-18 | 0 | 0 | 1 | 1 |
| Quarter Ending Mar-19 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 2 |
| Year Ending Dec-19 | 0 | 0 | 0 | 2 |
Earnings vs. 
Estimates- UPDATE 1-Rare manufacturing glitch raises concern over CAR-T therapies -study
- Rare manufacturing glitch raises concern over CAR-T therapies -study
- Express Scripts staking out million dollar gene therapies
- CORRECTED--Express Scripts staking out million dollar gene therapies
- RPT-FOCUS-Express Scripts staking out million dollar gene therapies